Published • loading... • Updated
Amneal Pharmaceuticals (NASDAQ:AMRX) Cut to “Strong Sell” at Zacks Research
Summary by thecerbatgem.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amneal Pharmaceuticals (NASDAQ:AMRX) Cut to “Strong Sell” at Zacks Research
Zacks Research lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks reports. Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $22.00 target price on shares of […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
